Anzeige
Mehr »
Freitag, 28.11.2025 - Börsentäglich über 12.000 News
Internationale Expansion geplant: Medizintechnik aus dem Weltraum!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PHHB | ISIN: US03828A1016 | Ticker-Symbol: 2UV
Tradegate
28.11.25 | 09:05
0,222 Euro
-3,23 % -0,007
1-Jahres-Chart
APPLIED THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
APPLIED THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,2240,23913:58
0,2240,23913:58

Aktuelle News zur APPLIED THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
APPLIED THERAPEUTICS Aktie jetzt für 0€ handeln
20.11.Applied Therapeutics prüft strategische Optionen und kündigt Stellenabbau an44
20.11.Applied Therapeutics explores strategic alternatives amid workforce cuts25
20.11.Applied Therapeutics, Inc. - 8-K, Current Report13
13.11.Applied Therapeutics Tanks As FDA Path For Lead Rare-Disease Drug Turns Uncertain85
13.11.Applied Therapeutics GAAP EPS of -$0.13 beats by $0.0374
13.11.Applied Therapeutics, Inc. - 10-Q, Quarterly Report32
13.11.Applied Therapeutics, Inc. - 8-K, Current Report28
29.09.Applied Therapeutics stock plunges after FDA meeting on CMT-SORD drug98
29.09.Applied Therapeutics meets with FDA on potential CMT-SORD drug43
29.09.Applied Therapeutics Provides Update Following Meeting with FDA275NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT) (the Company), a clinical-stage biopharmaceutical company dedicated to creating transformative treatments for...
► Artikel lesen
29.08.Applied Therapeutics, Inc. - 8-K, Current Report38
14.08.Applied Therapeutics GAAP EPS of -$0.15 beats by $0.0129
13.08.Applied Therapeutics, Inc. - 10-Q, Quarterly Report10
13.08.Applied Therapeutics, Inc. - 8-K, Current Report6
13.08.Applied Therapeutics Reports Second Quarter 2025 Financial Results321- CMT-SORD program advances; meeting scheduled with the FDA in Q3 2025 to discuss govorestat for the treatment of CMT-SORD - Presented full 12-month clinical results and new topline data from INSPIRE...
► Artikel lesen
17.06.Applied Therapeutics promotes two executives to leadership roles38
17.06.Applied Therapeutics Announces Key Leadership Appointments22
12.06.Applied Therapeutics, Inc. - 8-K, Current Report12
18.05.Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting475Slowing of progression of disease observed via MRI at 24 months Improvements in outcomes and reduction in sorbitol maintained through 24 months Statistically significant correlation between absolute...
► Artikel lesen
13.05.Applied Therapeutics Reports First Quarter 2025 Financial Results308- Company to present full 12-month clinical data and new topline 18-month and 24-month data from INSPIRE registrational Phase 3 trial of govorestat in CMT-SORD Deficiency at the Peripheral Nerve Society...
► Artikel lesen
Weiter >>
28 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
2,6,90